Endologix announces 150th patient enrolled in JAGUAR randomised controlled trial


Endologix recently announced the completion of the 150th case in the JAGUAR study.

This randomised controlled trial is evaluating Endologix’s Alto abdominal stent graft system, comparing its effectiveness to other commercially available endovascular aneurysm repair (EVAR) devices in the treatment of abdominal aortic aneurysms (AAA).

The JAGUAR (Objective analysis to gauge EVAR outcomes through randomisation) study is a prospective, randomised, multicentre trial, designed to enrol 450 patients at up to 60 sites. Three hundred patients will be randomly assigned to the Alto cohort, with 150 allocated to the comparator group. The study will follow-up patients through five years, with outcomes independently adjudicated.

“This milestone for Endologix underlines our dedication to clinical research and patient care,” stated Matt Thompson, president and CEO of Endologix. “The JAGUAR trial, our second randomised study aimed at assessing comparative endograft performance, follows in the footsteps of our successful LEOPARD study. We strongly believe in Alto’s role in managing AAA, given its low profile, wide applicability within EVAR and in the durability of the adaptive sealing technology. These evaluations are instrumental in shaping optimal treatment strategies and enhancing patient outcomes.”

A press release details that the Alto device utilises a low-profile delivery system and, unlike standard EVAR devices, features an exclusive adaptive sealing technology that moulds in-situ to the patient’s specific aortic neck anatomy.


Please enter your comment!
Please enter your name here